Thirty-One MPs Challenge Streeting’s Authority to Override NHS Drug Pricing Body

Thirty-one Members of Parliament have initiated a House of Commons motion to challenge the health secretary's new authority to influence drug pricing decisions by the National Institute for Health and Care Excellence, a move tied to a recent pharmaceutical agreement. This action highlights significant parliamentary concerns over the independence of the NHS drug appraisal body.

The National Institute for Health and Care Excellence (NICE) assesses the value for money of medicines and other health technologies for the National Health Service (NHS). Since its establishment in 1999, NICE has served as the independent arbiter for which drugs the NHS purchases in England and Wales, aiming to ensure cost-effectiveness. A recent statutory instrument now grants the health secretary, Wes Streeting, the power to direct NICE on the specific cost-effectiveness thresholds it applies when evaluating health technologies. This change is part of a broader UK-US pharmaceutical agreement, which also has trade implications.

Thirty-one MPs have formally signed a House of Commons motion opposing the health secretary's new power to override NICE's judgments on drug pricing. Former Shadow Chancellor John McDonnell stated these changes to NICE, stemming from the US pharmaceutical deal, compromise its independence. He argued this development risks giving US pharmaceutical companies undue influence over drug policies. McDonnell further cautioned that this could divert crucial NHS resources away from other life-saving practices and toward drug companies, potentially harming patients. Helen Morgan, Liberal Democrat health spokesperson, affirmed that the change to NICE rules is driven by external influence rather than by a belief it will genuinely benefit patients.

The challenge by these MPs signals significant parliamentary concern regarding the future of NHS drug procurement and its financial implications. The ability of the health secretary to direct NICE could fundamentally alter how new medicines are evaluated and adopted within the NHS. This shift may impact overall NHS budgets and potentially necessitate difficult trade-offs with other essential patient services. The motion represents a direct parliamentary pushback against executive power in a critical area of public health spending. Observers will closely monitor how this parliamentary motion progresses and its potential long-term effects on the impartiality and independence of NHS drug appraisal processes.